Federal Register Notice: FDA’s Oncologic Drugs Advisory Committee will meet 6/25 from 8:30 a.m. to 3:30 p.m. at the FDA White Oak Campus to discuss an AstraZeneca NDA for olaparib capsules for use as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed ovarian cancer (including fallopian tube or primary peritoneal) with germline BRCA mutation as detected by an FDA-approved test, who are in response (complete response or partial response) to platinum-based chemotherapy. Contact Caleb Briggs, (301) 796-9001. To view this notice, click here.